中华放射肿瘤学杂志
Sunday, Apr. 6, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2022, Vol. 31 Issue (2): 219-222    DOI: 10.3760/cma.j.cn113030-20200619-00315
Review Articles Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on the role of IDO signaling pathway in radiotherapy for non-small cell lung cancer
Wu Linfang1, Wang Chunyu1, Yang Yufan1, Bi Nan1, Wang Lyuhua1,2
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
2National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China
Download: PDF (790 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Indoleamine 2,3-dioxygenase (IDO) is one of the rate-limiting enzymes that degrade tryptophan (Trp) into kynurenine (Kyn). Inflammatory factor IFN-γ mediates tumor′s immune escape by activating the IDO signaling pathway, upregulating theKyn/Trp (K/T ratio) and suppressing the activity of both CD+8T and regulatory T cells. Radiotherapy plays a major role in treating non-small cell lung cancer. It not only bi-directionally regulates immune response of the host, but also collaborates with immunosuppressive agents to kill tumors. Meanwhile, immune status of the host can affect the therapeutic effect of radiotherapy. In recent years, studies have shown that IDO activity levels change before and after radiotherapy and is related to clinical prognosis. Nevertheless, relevant mechanism remains unclear. This article aims to elucidate the application of IDO signaling pathway in radiotherapy for non-small cell lung cancer.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Wu Linfang
Wang Chunyu
Yang Yufan
Bi Nan
Wang Lyuhua
Key wordsIndoleamine 2,3-dioxygenase      Neoplasm, non-small cell lung/radiotherapy      Immune     
Received: 19 June 2020     
Corresponding Authors: Wang Lyuhua;Email:wlhwq@yahoo.com   
Cite this article:   
Wu Linfang,Wang Chunyu,Yang Yufan et al. Research progress on the role of IDO signaling pathway in radiotherapy for non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 219-222.
Wu Linfang,Wang Chunyu,Yang Yufan et al. Research progress on the role of IDO signaling pathway in radiotherapy for non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 219-222.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200619-00315     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I2/219
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn